Noticias y Actividades de Third Rock Ventures

Ver el organigrama con sus 34 ejecutivos principales

Biografías más buscadas en Third Rock Ventures

• Robert Tepper, Founding Partner, Formation, Development and Scient...
• Chris Robinson, Chief Talent Officer
• Kevin Gillis, Partner and Chief Operating Officer

Crear su alerta
para seguir los movimientos de los ejecutivos en Third Rock Ventures.

Third Rock Ventures tiene 1.642 competidores entre los que se incluyen Griffin Gaming Partners (Estados Unidos), BlackRock (Estados Unidos) y KKR (Estados Unidos).

Popular M&A news in Fondo

• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (publicado el 3 de junio de 2026).
• Prime Capital Financial ha Access Capital Partners adquirido (publicado el 2 de junio de 2026).
• Frazier Healthcare Partners ha Altruix adquirido (publicado el 29 de mayo de 2026).

Otros contactos sugeridos en el sector Fondo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer en Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director en Vanguard
• Scott Nuttall - Co-Chief Executive Officer and Director en KKR

Saber más sobre el sector Fondo

Últimos comunicados de prensa de Third Rock Ventures

• Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference » Rapport Therapeutics, Inc.
• Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | Tango Therapeutics, Inc
• Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update » Rapport Therapeutics, Inc.
• Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results - Mon, 05/11/2026 - 16:01
• Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | Maze Therapeutics
• Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting » Rapport Therapeutics, Inc.
• Clasp Therapeutics Unveils First-in-Class KRas T Cell Engager CLSP-5282 at AACR 2026 — Clasp Tx
• Maze Therapeutics Announces $150 Million Registered Offering | Maze Therapeutics
• Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism - Mon, 04/13/2026 - 08:00
• Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia | Terremoto
• View more press releases Close

Redes sociales sobre Third Rock Ventures

• Third Rock Ventures en Wikipedia, Google News y Yahoo Finance
• Third Rock Ventures en LinkedIn, Twitter y YouTube